Last reviewed · How we verify
NCT03371056: InSPIRe
Maternal- Fetal Infection
NA trial testing Bacteriological analyses on clinical samples performed with swabs in Neonatal Infection in 2,569 participants. Completed in 30 December 2023.
30 August 2023
Quick facts
| Lead sponsor | Assistance Publique - Hôpitaux de Paris |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | screening |
| Enrollment | 2,569 |
| Start date | 28 August 2018 |
| Primary completion | 30 August 2023 |
| Estimated completion | 30 December 2023 |
| Sites | 3 locations across France |
Drugs / interventions tested
- Bacteriological analyses on clinical samples performed with swabs — full drug profile →
Conditions studied
- Neonatal Infection — all drugs for Neonatal Infection →
Sponsor
Assistance Publique - Hôpitaux de Paris — full company profile →
Who can join
18 and older, female only, with Neonatal Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of the protocol is to validate a novel point of care multiplex system to detect and characterize microorganisms responsible for neonatal sepsis, as well as biomarkers of infection, from a simple vaginal sample, in order to improve the prevention of perinatal bacterial infections.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT03371056
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neonatal Infection
Currently open trials in the same condition.
- NCT06592586 — A Follow-up Trial of GBS-NN/NN2 Vaccine in Healthy Pregnant Women · Phase 2, PHASE3 · active not recruiting
- NCT06656104 — Impact of a Multi-infusion Strategy in Neonatology on the Rate of Central Line-associated Bloodstream Infections · recruiting
- NCT06102044 — Zinc Supplementation for Young Infants With Clinical Severe Infection in Tanzania · Phase 3 · recruiting
- NCT06283355 — Comparing Single Versus Repeat NMT on the Diversity of the Neonatal Nasal Microbiome · Phase 1 · recruiting
- NCT05695196 — Feasibility and Safety Study of Parent-to-Child Nasal Microbiota Transplant · Phase 1 · active not recruiting
Other Assistance Publique - Hôpitaux de Paris trials
Trials by the same sponsor.
- NCT07443436 — Immunomodulatory Treatment of Interstitial Lung Disease Associated With Surfactant Related Gene Variants · Phase 2 · not yet recruiting
- NCT07499492 — Red Blood Cell Transfusion to Optimize Extubation · NA · not yet recruiting
- NCT07379918 — Real-life Evaluation of Endopredict® in Early HR+/HER2- Breast Cancer · recruiting
- NCT07473869 — Smartphone Application for Automated Measurement of Capillary Refill Time (CRT) · not yet recruiting
- NCT07505394 — Efficacy of a Prediction Model-based Algorithm to PREVENT Drug-induced Impulse Control Disorders in Parkinson's Disease · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03371056 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Assistance Publique - Hôpitaux de Paris
- Last refreshed: 3 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03371056.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing